INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

INOVIO (NASDAQ: INO) will release its fourth quarter and year-end 2020 financial results on March 1, 2021, after market close.

Rhea-AI Summary

INOVIO (NASDAQ: INO) will release its fourth quarter and year-end 2020 financial results on March 1, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide updates on the company's DNA Medicines Platform, particularly its COVID-19 vaccine development. INOVIO, a pioneer in DNA medicines, is advancing clinical trials for its lead candidate VGX-3100, which targets precancerous cervical dysplasia linked to high-risk HPV types 16 and 18.

Positive

• Upcoming release of Q4 and full-year 2020 financial results could signal improved financial health.
• Continuing clinical trials for VGX-3100 demonstrate ongoing commitment to innovative treatments.
• Potential insights on COVID-19 vaccine developments during upcoming conference call.

Negative

• None.

Argus Session date unavailable

-3.09% session move Open Argus

Details

News Market Reaction – INO

The recorded move for INO in the trading session of this news was -3.09%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., Feb. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that fourth quarter and year-end 2020 financial results will be released after the market close on March 1, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.

A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.

CONTACTS:
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com
Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com

 

View original content:http://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-1-2021-301228715.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will INOVIO report its fourth quarter and year-end 2020 financial results?

INOVIO will report its financial results on March 1, 2021, after market close.

What time will the INOVIO conference call take place?

The conference call will take place at 4:30 p.m. ET on March 1, 2021.

What is INOVIO's lead candidate in clinical trials?

INOVIO's lead candidate is VGX-3100, which is currently in Phase 3 trials for precancerous cervical dysplasia.

What platform will INOVIO discuss during the conference call?

INOVIO will discuss its DNA Medicines Platform and updates on vaccine developments for COVID-19.